Immuneering Corporation (NASDAQ:IMRX – Get Free Report) CEO Benjamin Zeskind bought 2,400 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were acquired at an average price of $4.56 per share, with a total value of $10,944.00. Following the completion of the acquisition, the chief executive officer directly owned 2,315,252 [...]